Large cap biotech stocks performed much better than small and mid caps last year. Will this development continue or is a change in sight? Will M&A activity increase again this year and which indications and technologies will be in particular focus? These and other questions are explored in the video update with Dr. Daniel Koller, Head of the Investment Management Team.

Technological progress is the basis for the transformation of many disease areas, with mRNA, siRNA and ASO-based drugs playing a particularly important role. Antibody drug conjugates or gene therapies are also in the focus of interest, where important development steps are expected. Last but not least, M&A activities and partnerships are likely to increase.

Sustainability is an important factor in BB Biotech’s business strategy. It is a key component in ensuring our long-term success while creating added value for all our shareholders and other stakeholders. We seek to achieve growth while also taking into account the needs of the environment and society. As an investment company, we are in a position to promote sustainable development for the benefit of all our stakeholders.